We used thalidomide to treat 10 patients with advanced stage multiple myeloma who had failed to obtain at least a partial response after a VAD-based induction therapy. Seven out 10 cases achieved clinical and histologic responses and proceeded to collection of peripheral blood stem cells and transplantation and ASCT.
